Naval Daver, MD / Joseph D. Khoury, MD, FCAP - The Pathology–Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes - a podcast by PVI, PeerView Institute for Medical Education
from 2020-11-13T18:00
Go online to PeerView.com/PDK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist-oncologist panel discusses how modern, team-based treatment decisions are guided by the results of molecular/pathology testing across a wide range of acute myeloid leukemia (AML) settings, while also profiling how new evidence influences pathologic assessment and treatment selection across the continuum of AML care. Upon completion of this activity, participants should be better able to: Identify specific molecular and histopathologic features that can inform the diagnosis of different AML subtypes, including secondary AML/AML-MRC or FLT3- or IDH-mutant AML, Select appropriate evidence-based molecular/pathology tests to confirm a diagnosis of AML, Develop molecular testing strategies to collect relevant information over the course of the AML treatment continuum, Recommend appropriate, safe management options for patients with diverse AML subtypes in collaboration with the wider oncology management team.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education